



SpyGlass Pharma to Participate in Upcoming Investor Conferences

September 2, 2026

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:

Wells Fargo 21st Annual Healthcare Conference

Date: Wednesday, September 9, 2026

Format: 1x1 Meetings only

Citi's 2026 Biopharma Back to School Conference

Date: Thursday, September 10, 2026

Time: 10:40 a.m. ET

Format: Fireside Chat and 1x1 Meetings

H.C. Wainwright 28th Annual Global Investment Conference

Date: Monday, September 14, 2026

Time: 1:30 p.m. ET

Format: Corporate Presentation & 1x1 Meetings

A live webcast and subsequent replay of the Citi fireside chat and H.C. Wainwright presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com.

About SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company's mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.

The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.

Media Contact:

Nami Surendranath

+1 (402) 507-6757

nsurendranath@dnacommunications.com

Investor Contact:

Ami Bavishi or Nick Colangelo

Gilmartin Group LLC

investors@spyglasspharma.com